Coronavirus disease-19 and rheumatological disorders: A narrative review
The global spread of coronavirus disease-19 (COVID-19) caused by severe acute respiratory syndrome coronavirus-2, which originated from Wuhan, China, is likely to have an impact on the rheumatological practices due to a dilemma in both continuing and initiating immunosuppressive medications. We revi...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2020-01-01
|
| Series: | Indian Journal of Rheumatology |
| Subjects: | |
| Online Access: | http://www.indianjrheumatol.com/article.asp?issn=0973-3698;year=2020;volume=15;issue=2;spage=122;epage=129;aulast=Chattopadhyay |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849469538660253696 |
|---|---|
| author | Arghya Chattopadhyay Debashish Mishra Vikas Sharma G SRSN K Naidu Aman Sharma |
| author_facet | Arghya Chattopadhyay Debashish Mishra Vikas Sharma G SRSN K Naidu Aman Sharma |
| author_sort | Arghya Chattopadhyay |
| collection | DOAJ |
| description | The global spread of coronavirus disease-19 (COVID-19) caused by severe acute respiratory syndrome coronavirus-2, which originated from Wuhan, China, is likely to have an impact on the rheumatological practices due to a dilemma in both continuing and initiating immunosuppressive medications. We reviewed the risk stratification of patients with rheumatological disorders, the safety of various anti-rheumatological drugs, and the role of multiple drugs used by the rheumatologists in managing COVID-19. The score-based risk stratification is helpful in therapeutic decision-making such as self-isolation, continuation, or initiation of immunosuppressive therapy. Most of the immunosuppressive therapies need not be discontinued unless there is an overwhelming infection. The treatment interruption should not be made in fear, and there should be shared decision-making in consultation with the patient. The proposed role of different anti-rheumatic drugs such as hydroxychloroquine and tocilizumab in COVID-19 based on some initial uncontrolled trials and case reports will become clearer when the results of various ongoing well-planned studies become available. |
| format | Article |
| id | doaj-art-fd7ece374f834ca5b0cadd3a89e2cb26 |
| institution | Kabale University |
| issn | 0973-3698 0973-3701 |
| language | English |
| publishDate | 2020-01-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Indian Journal of Rheumatology |
| spelling | doaj-art-fd7ece374f834ca5b0cadd3a89e2cb262025-08-20T03:25:26ZengSAGE PublishingIndian Journal of Rheumatology0973-36980973-37012020-01-0115212212910.4103/injr.injr_73_20Coronavirus disease-19 and rheumatological disorders: A narrative reviewArghya ChattopadhyayDebashish MishraVikas SharmaG SRSN K NaiduAman SharmaThe global spread of coronavirus disease-19 (COVID-19) caused by severe acute respiratory syndrome coronavirus-2, which originated from Wuhan, China, is likely to have an impact on the rheumatological practices due to a dilemma in both continuing and initiating immunosuppressive medications. We reviewed the risk stratification of patients with rheumatological disorders, the safety of various anti-rheumatological drugs, and the role of multiple drugs used by the rheumatologists in managing COVID-19. The score-based risk stratification is helpful in therapeutic decision-making such as self-isolation, continuation, or initiation of immunosuppressive therapy. Most of the immunosuppressive therapies need not be discontinued unless there is an overwhelming infection. The treatment interruption should not be made in fear, and there should be shared decision-making in consultation with the patient. The proposed role of different anti-rheumatic drugs such as hydroxychloroquine and tocilizumab in COVID-19 based on some initial uncontrolled trials and case reports will become clearer when the results of various ongoing well-planned studies become available.http://www.indianjrheumatol.com/article.asp?issn=0973-3698;year=2020;volume=15;issue=2;spage=122;epage=129;aulast=Chattopadhyaycoronavirus disease-19hydroxychloroquinerheumatologysevere acute respiratory syndrome coronavirustocilizumab |
| spellingShingle | Arghya Chattopadhyay Debashish Mishra Vikas Sharma G SRSN K Naidu Aman Sharma Coronavirus disease-19 and rheumatological disorders: A narrative review Indian Journal of Rheumatology coronavirus disease-19 hydroxychloroquine rheumatology severe acute respiratory syndrome coronavirus tocilizumab |
| title | Coronavirus disease-19 and rheumatological disorders: A narrative review |
| title_full | Coronavirus disease-19 and rheumatological disorders: A narrative review |
| title_fullStr | Coronavirus disease-19 and rheumatological disorders: A narrative review |
| title_full_unstemmed | Coronavirus disease-19 and rheumatological disorders: A narrative review |
| title_short | Coronavirus disease-19 and rheumatological disorders: A narrative review |
| title_sort | coronavirus disease 19 and rheumatological disorders a narrative review |
| topic | coronavirus disease-19 hydroxychloroquine rheumatology severe acute respiratory syndrome coronavirus tocilizumab |
| url | http://www.indianjrheumatol.com/article.asp?issn=0973-3698;year=2020;volume=15;issue=2;spage=122;epage=129;aulast=Chattopadhyay |
| work_keys_str_mv | AT arghyachattopadhyay coronavirusdisease19andrheumatologicaldisordersanarrativereview AT debashishmishra coronavirusdisease19andrheumatologicaldisordersanarrativereview AT vikassharma coronavirusdisease19andrheumatologicaldisordersanarrativereview AT gsrsnknaidu coronavirusdisease19andrheumatologicaldisordersanarrativereview AT amansharma coronavirusdisease19andrheumatologicaldisordersanarrativereview |